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MicroAbstract: 
Many ES-NSCLC patients develop metastases after SBRT. We retrospectively analyzed multiple 
variables in 406 lesions to develop a predictor for metastatic failure. GTV volume and prescription 
dose were significantly associated with metastases. A metastasis risk score tool was developed to 
identify patients at higher risk for metastases after lung SBRT who might benefit from enrollment 
in future trials evaluating the benefit of adjuvant or intensified treatment. 
Abstract 
Introduction/Background: 
Many early-stage non-small cell lung cancer (ES-NSCLC) patients undergoing stereotactic body 
radiation therapy (SBRT) develop metastases, which is associated with poor outcomes. We sought 
to identify factors predictive of metastases after lung SBRT and created a risk stratification tool. 
Materials and Methods: 
We included 363 patients with ES-NSCLC who received SBRT; median follow-up was 5.8 years. 
The following patient and tumor factors were retrospectively analyzed for their association with 
metastases (defined as nodal and/or distant failure): sex; age; lobe involved; centrality; previous 
NSCLC; smoking status; gross tumor volume (GTV); T-stage; histology; dose; minimum, 
maximum, and mean GTV dose; and parenchymal lung failure. A metastasis risk-score linear-
model using beta coefficients from a multivariate Cox model was built. 
Results: 
A total of 111/406 (27.3%) lesions metastasized. GTV volume and dose were significantly 
associated with metastases on univariate and multivariate Cox proportional hazards modeling 
(p<0.001 and HR=1.02 per mL, p<0.05 and HR=0.99 per Gy, respectively). Histology, T-stage, 
centrality, lung parenchymal failures, and previous NSCLC were not associated with development 
of metastasis. A metastasis risk-score model using GTV volume and prescription dose was built: 
[risk score=(0.01611 x GTV)–(0.00525 x dose (BED10))]. Two risk-score cutoffs separating the 
cohort into low-, medium-, and high-risk subgroups were examined. The risk-score identified 
significant differences in time to metastases between low-, medium-, and high-risk patients 
(p<0.001), with 3-year estimates of 81.1%, 63.8%, and 38%, respectively. 
Conclusion: 
GTV volume and radiation dose are associated with time to metastasis and may be used to identify 
patients at higher risk of metastasis after lung SBRT. 
Key words: SBRT, SABR, radiation, stereotactic body ablative radiotherapy, metastasis 
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Introduction 
The current standard of care for early-stage non-small cell lung cancer (NSCLC) without lymph 
node involvement is tumor resection with hilar and mediastinal node dissection. For patients who 
are medically inoperable or refuse surgery, stereotactic body radiation therapy (SBRT), also 
known as stereotactic ablative radiotherapy, is the standard of care. Multiple reports have shown 
excellent rates of local control after SBRT for early-stage NSCLC [1-6]. The Radiation Therapy 
Oncology Group conducted a phase II trial (RTOG 0236) evaluating the efficacy of SBRT for 
patients with peripherally located tumors. The reported 3-year local control (LC) rate was 98% 
with a 3-year overall survival (OS) of 56% and a median OS of 4 years [1]. A pooled analysis of 
two prematurely closed randomized trials comparing SBRT vs. lobectomy for operable stage I 
(T1-2aN0M0) NSCLC patients suggested at least clinical equipoise between SBRT and surgery, 
with a 3-year OS of 95% vs. 79%, respectively [3]. A meta-analysis of 40 SBRT studies (4850 
patients) and 23 surgery studies (7071 patients) concluded that overall and disease free survival 
are similar after adjustments for operability and age [7]. 
Adjuvant chemotherapy after surgical resection has been shown to improve survival in certain 
patients with NSCLC [8]. This finding raises the question of whether adjuvant chemotherapy 
after lung SBRT could potentially benefit those at risk for metastatic failure. Predicting patients 
at increased risk for disease recurrence after SBRT could help guide treatment and lead to 
improved patient outcomes. Multiple studies have reported nodal and distant metastatic 
recurrence rates after lung SBRT for early stage NSCLC [2, 9-11]. The original Indiana 
University phase II study reported 8.6% nodal and 12.9% distant metastatic failure rates with a 
median follow up of 50 months [2]. RTOG 0236 reported a 3-year rate of disseminated failure of 
22.1% and a 5-year rate of 23.6% [1, 12]. The 5-year rate of regional failure was 10.9% [12]. 
The recently published SPACE trial (Stereotactic Precision And Conventional radiotherapy 
Evaluation) reported a distant failure rate of 24% and a regional failure rate (excluding local 
failures) of 7% after SBRT [4]. In a large single-institution retrospective analysis of 676 patients 
treated with SBRT, with a median follow up of 32.9 months, the 2-year rates of regional and 
distant recurrences were 7.8% and 14.7%, respectively. At 5 years, the rates were 12.7% and 
19.9%, respectively [10]. A review of 16 articles on SBRT in early stage NSCLC reported that 
the cumulative incidence of regional recurrences after SBRT varied from 0 to 28.6%, with a 
mean incidence of 9.6% [11]. RTOG 0236 reported a 3-year distant metastatic recurrence rate of 
5.9% for squamous cell carcinomas vs. 30.7% for non-squamous histologies, and 5-year rates of 
5.9% and 31.6%; though not statistically significant [1, 12]. Moreover, the 5-year distant 
metastatic rates were 18.% for T1 tumors and 45.5% for T2 tumors [12].  
Only a few studies have explored associations between clinical factors and the risk of nodal or 
distant metastatic failure after SBRT. A small study of 81 patients identified tumor size (<2.5 vs. 
>2.5cm), location (central vs. peripheral), stage (IA vs. IB), and use of certain drugs (metformin,
statin, ACE inhibitor) as risk factors for distant metastasis; the final model achieved a 0.80
receiver operating characteristic (ROC) area under the curve (AUC) [13]. A similar effort using a
larger cohort of 729 patients identified age, tumor size, FDG avidity, and presence of
synchronous primaries as potential predictors of distant metastatic disease [14]. A nomogram
built from these variables and several additional factors (body mass index (BMI), Charlson
Comorbidity Index, medical operability) had a c-statistic of 0.606 [14]. Due to the limited
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
available data and the clinical implications of metastatic failure for these patients, we sought to 
identify risk factors for metastatic recurrence after lung SBRT for early stage NSCLC. 
Materials and methods 
Study population 
This study was an Institutional Review Board-approved retrospective review of outcomes after 
SBRT for NSCLC among patients treated between 2000 and 2016. All patients had provided 
informed consent for radiation therapy at the time of treatment. Patients were identified by 
medical billing codes or relevant billing information. Eligible patients were ≥18 years of age 
with histologically or clinically diagnosed early stage NSCLC; synchronous lesions were 
included. A clinical diagnosis of NSCLC in patients who could not undergo or refused biopsy 
was based on radiographic suspicion, most often via review of serial chest CT scans in the 
setting of a multidisciplinary thoracic tumor board. Patients treated with SBRT were either 
medically inoperable or had refused surgery. Patients were excluded if they had evidence of 
systemic spread of lung cancer at the time of SBRT. Radiation planning and treatment details 
have been previously reported [15]. Prescriptions typically were to the 80% isodose line, and the 
prescription typically covered at least 95% of the PTV. More recently in the intensity-modulated 
radiation therapy setting, prescriptions were typically 95% of the PTV receiving 100% of the 
prescription and 99% of the internal target volume receiving at least 110% of the prescription. 
The most common dose fractionations are included in Table 1. 
Data collection 
The date of diagnosis was defined as the date of tumor sampling for those with a histologic 
diagnosis or the date of imaging prompting additional work up for those with a clinical 
diagnosis. The date of last follow-up was defined as the date the patient last visited with a 
radiation oncologist, medical oncologist, surgical oncologist, or pulmonologist. American Joint 
Committee on Cancer 7th edition (AJCC 7e) staging guidelines were used for all cases. Follow-
up was done at the discretion of the treating physician. Follow-up imaging most often was by CT 
or positron emission tomography-CT (PET-CT). Recurrences were diagnosed by review of the 
patient’s serial imaging and the clinical judgement of treating physicians. Distant sites were 
defined per AJCC 7e staging, with two exceptions: synchronous tumors were staged 
independently, and metachronous lung parenchymal lesions were staged as new primary lung 
cancers. Thus, limited contralateral lung parenchymal failures were considered a lung 
parenchymal failure and not a distant metastatic failure. Of note, only one patient in this cohort 
had three lung parenchymal failures over the course of seven years following SBRT before nodal 
or distant metastases were detected. All of the failures were managed with SBRT (one photon 
and two proton courses; proton courses not included in this analysis). Tumors were considered to 
be in a central location if the tumor’s planning target volume (PTV) was located within 2 cm of 
the proximal tracheobronchial tree [16]. 
Statistical analysis 
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OS was calculated using the Kaplan-Meier method from the date of diagnosis until death or last 
follow-up. Time to metastases was defined as time from date of diagnosis to first nodal or distant 
metastasis, whichever occurred first, and censored at death or last follow-up. Age, smoking 
status (current, former, never, unknown), gross tumor volume (GTV), radiation prescription dose 
(biologically effective dose using a tumor alpha/beta=10 [BED10]), and minimum, maximum, 
and mean dose to GTV (all in BED10) were considered continuous variables. Sex, lobe involved, 
location (central vs. peripheral), previous history of NSCLC, T stage, histology 
(adenocarcinoma, squamous cell carcinoma, NSCLC not otherwise specified, or no pathology), 
and parenchymal lung failure (local failure, same lobe non-local failure, other ipsilateral lobe 
failure, and contralateral lung failure) were considered categorical variables. Univariate analyses 
were used to determine the association between the aforementioned variables and time to 
metastatic failure. Significant variables on univariate analyses were then entered into the 
multivariate analyses. In addition, borderline significant radiation dose variables were also 
evaluated in separate multivariate analyses. A metastasis risk score linear model was built using 
beta coefficients from the multivariate Cox proportional hazards model (Table 3, model 1 using 
prescription dose instead of minimum, mean, or maximum dose because of ease of use and the 
ability to use the model before radiation planning is complete) as weighting factors for variables 
significant on multivariate analysis. Cutoffs were manually explored for risk score groupings and 
cutoffs -0.1 and -0.8 were used for further analysis as they were associated with the biggest 
differences in metastatic failure outcomes (see Figure 1). The performance of the metastasis risk 
score was evaluated by determining the C-index using the Bioconductor/R rms (version 5.1-2) 
package by validation of the model using bootstrap (for details see table S2).  
Results 
From 2000 to 2016, 363 patients with 406 lesions met eligibility criteria and were treated with 
SBRT. Table 1 summarizes patient demographics and baseline characteristics. The majority of 
patients (n = 199, 54.8%) were women, and median age was 73.2 years (range 44.1 – 93.8). The 
most common histologies were adenocarcinoma (40.8%), squamous cell carcinoma (32.2%), and 
NSCLC not otherwise specified (17.4%); 9.6% were diagnosed clinically without pathologic 
confirmation. Overall, 117 (28.8%) lesions were treated in the setting of presumed previously 
cured NSCLC. Patients were treated to a median BED10 of 105.6 Gy (range 72- 244.8 Gy). All 
patients had early-stage disease: 151 had T1a (41.6%), 120 T1b (33.1%), and 92 T2a (25.3%) 
tumors. At least 93.5% of lesions were PET-staged. Only 6% of patients underwent invasive 
mediastinal staging, mostly by EBUS, at the treating physician’s discretion. Median follow-up 
was 5.8 years. 
Most patients had durable disease control; 252/406 lesions (62.1%) and 224/363 patients (61.7%) 
never recurred after SBRT. Nodal and/or distant failure occurred in 111/406 (27.3%) total 
lesions, with a median time to first metastatic failure of 465 days (56 – 3784 days). The pattern 
of failure is as follows: 50 lesions had solely distant failure, 41 lesions had solely nodal failure, 
and 20 lesions failed in both sites. The remaining 43 lesions had either local or other 
parenchymal sites of failure, without nodal or distant failure. 
Seventy of 406 (17.2%) lesions failed distantly, with a median time to distant failure of 375 days 
(range 56 – 2704). The 1-, 2-yr, and 3-yr distant metastases-free survival rates were 94.6%, 
84.4%, and 77.7%, respectively. Median OS for patients with distant failure was 20 months 
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(range 3.8 – 90.9 months). Nodal failure occurred in 61/406 (15.0%) lesions, with a median time 
to nodal failure of 525 days (range 118 – 3784). Rates of 1-, 2-, and 3-year nodal metastases-free 
survival were 96.2%, 89.2%, and 76.7%, respectively. Median OS for patients with nodal failure 
was 25.5 months (range 5.2 – 131.7). Of the 20 lesions (4.9%) that had both distant and nodal 
failure, 9 were detected simultaneously, and 11 were detected at different times: 8 in nodes first 
and 3 distantly first.  
 
GTV volume (p <0.005), GTV minimum dose (p<0.05), and GTV mean dose (p<0.05) were 
significantly associated with the development of metastases on univariate analysis. Radiation 
prescription dose, GTV maximum dose, histology, T stage, tumor centrality (figure S1), previous 
history of NSCLC (figure S2), or lung parenchymal failure after SBRT were not associated with 
the development of metastases (p>0.05). Risk factors for individual failures are summarized in 
Table 2.  
 
On multivariate Cox proportional hazards modeling (Table 3, Table S1), GTV mean dose and 
GTV volume remained significantly associated with time to metastasis (p=0.042 and HR=0.99 
per Gy and p<0.001 and HR=1.02 per mL, respectively). Similarly, GTV volume and radiation 
prescription dose were significantly associated with time to metastasis on multivariate analysis 
(p<0.001, and p=0.044, respectively), as were GTV maximum dose and GTV volume (p=0.04 
and 0.0003, respectively). Based on these findings, a metastasis risk score model using GTV (in 
mL) and radiation prescription dose (in Gy) was built (see Table S2):  
 
  [Risk score = (0.01611 x GTV) – (0.00525 x prescription dose (BED10))].  
 
The distribution of risk scores in our cohort is shown in Figure 1. Consistent with its design, the 
risk score was significantly associated with time to metastatic failure (HR=2.7, p<0.001). To 
illustrate the impact of the risk score on metastatic failure, two risk score cutoffs (-0.8 and -0.1) 
separating the cohort into low- (<-0.8), medium- (-0.8 to -0.1), and high-risk (>-0.1) groups were 
examined (figure 2 and S2). The risk score identified significant differences in time to metastases 
between 61 low risk, 264 medium risk, and 38 high risk patients (p<0.001). The 1-, 2-, and 3-
year metastasis-free survival rates for the low-, medium-, and high-risk groups were 96.0%, 
86.7%, and 81.1%; 93.8%, 81.3%, and 63.8%; and 81.5%, 48.8%, and 38.0%, respectively (p < 
0.0001, table 4). Respective median OS times for the low-, medium-, and high-risk groups were 
28.2 (range 2.4 –143.9), 19.9 (range 0.3 – 178.1), and 15.5 months (range 1.4 – 69.3). The 1-yr, 
2-yr, and 3-yr OS rates for the low-, medium-, and high-risk groups were 96.0%, 86.7%, and 
83.9%; 95.2%, 86.3%, and 78.4%; and 87.9%, 64.5%, and 57.3%, respectively. 
 
Discussion 
This study represents one of the first and largest studies dedicated to developing a risk score for 
either nodal or distant metastatic failure after treatment with SBRT for early stage NSCLC. 
Distant metastasis rates in our cohort (17%) were similar to most published series; however, the 
observed crude nodal failure rate (15%) as well as nodal metastasis-free survival in our cohort 
was slightly higher than previous published series [2, 4, 10].Together, a crude metastatic failure 
rate of 27% provided sufficient events (n=111) to reasonably conduct the presented study. 
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We identified radiation dose and GTV volume to be independently associated with metastatic 
failure. Our data suggests that lower prescription dose was associated with increased metastatic 
failure independent of GTV volume. To our knowledge, this is the first study to demonstrate the 
combined importance of GTV volume and radiation dose for metastatic failure risk. Other 
studies have also reported on associations between tumor size and the development of metastases 
after SBRT. In a phase II study by Baumann et al., T2 lesions were associated with significantly 
increased regional and distant recurrences at 3 years compared to T1 lesions [17]. RTOG 0236 
reported similar findings [12]. Allibhai et al. prospectively analyzed 185 medically inoperable 
patients with T1-2N0M0 NSCLC who received SBRT. With a median follow up of 15.2 months, 
they found that larger GTV volume was a predictor for worse distant relapse-free survival [18]. 
Other studies similarly have shown that larger tumor size is associated with the development of 
distant metastasis [13, 14]. However, tumor size was reported to not be associated with nodal 
failure after SBRT in a single institutional study [19]. Studies evaluating the presence of occult 
nodal metastases using invasive staging in patients with a PET-negative mediastinum suggest 
that larger tumor size and central tumor location are associated with nodal metastasis [20, 21]. 
The details of a possible association between tumor size and the development of nodal 
metastases after SBRT remain to be determined. Radiation dose has been previously reported to 
be associated with a reduced nodal and distant metastasis failure rate. In a 91-patient study, 
prescription dose, but not GTV or PTV, was the only factor associated with combined nodal or 
distant metastatic failure risk [22]. 
Strengths of our study include the large number of events and long follow up. Limitations 
inherent in retrospective analyses also apply to our study. Moreover, our study included patients 
who were treated for presumed second primary NSCLC, and it is possible that some metastases 
were actually from a previously treated NSCLC. Of note, having a history of NSCLC that was 
previously treated and thought to be cured was not associated with the development of 
metastases in our cohort. Also, the availability and use of EBUS evolved over time, and only a 
small percentage of patients in this cohort underwent invasive mediastinal staging prior to SBRT. 
This difference may have resulted in selection bias, as it is possible that patients with larger 
central lesions, who are traditionally thought to be at higher risk for occult nodal metastasis [21], 
were more likely to undergo EBUS. This difference might also explain why centrality was not 
associated with metastasis in the studied cohort. We aim to increase the use of EBUS staging for 
our patients in the future. It remains unclear why GTV volume was found to be a significant 
predictor of metastatic failure, but T stage was not. While the combination of nodal and distant 
metastasis for this analysis increased the number of events, certain tumor, patient, or treatment 
factors associated with the risk of nodal vs. distant failure may differ, and our model was not 
able to account for these potential differences. Furthermore, it remains to be seen how this model 
performs on other lung SBRT cohorts with a different mix of patients, tumors, and treatments. 
Moreover, the prescription doses evaluated in this study represent only a subset of accepted and 
commonly used prescription doses. Thus, it remains unclear if our results translate to 
prescription doses other than the ones evaluated here. Clearly, independent validation is needed 
to determine the predictive ability of the identified signature. 
In conclusion, we identified tumor volume and radiation dose to be associated with the 
development of metastases after SBRT for early stage NSCLC. Identification of patients at high 
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risk for the development of metastases may inform future studies evaluating treatment 
intensification strategies (e.g., adjuvant chemotherapy or immunotherapy) for such patients. 
Clinical Practice Points 
Unfortunately, many early stage NSCLC (ES-NSCLC) patients develop metastasis even after 
successful local treatment with stereotactic body radiation therapy (SBRT), suggesting the 
presence of occult metastases at initial diagnosis. Upfront identification of patients at highest risk 
for metastasis would allow to select patients for additional workup to minimize the risk of 
harboring undetected metastases. We now aimed to not only identify factors predicting 
metastatic failure after lung SBRT for ES-NSCLC patients but also build a nomogram that can 
be used as a clinical decision tool for assessing patients that may benefit from undergoing more 
invasive staging procedures such as endobronchial ultrasound (EBUS) for mediastinal staging. 
We were able to identify factors associated with a higher risk of nodal and/or distant failure and 
build such a nomogram. Using this tool patients can be classified according to tumor size and 
radiation dose into low, intermediate, and high risk for metastases. The nomogram predicted 
metastasis free survival rates at 3-years are 81.1%, 63.8%, and 38% for the respective risk 
groups. We propose that i) patients at high risk for metastatic failure may benefit from EBUS if 
there are no strict contraindications, and ii) patients with low and intermediate risk should be 
counseled on the risks and benefits of additional staging. 
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Table 1. Patient and lesion characteristics. 
Patient characteristics. 
Study cohort 
(n=363) 
Median age (range), yrs 73.2 (44.1-93.8) 
Sex (%) Female 199 (54.8%) 
Male 164 (45.2%) 
Smoking 
Current smokers 90 (24.8%) 
Former smokers 224 (61.7%) 
Never smokers 14 (3.9%) 
Unknown 35 (9.6%) 
 Lesion characteristics. n (%) 
Prior history of NSCLC 
Yes 117 (28.8) 
No 289 71.2 
Histology 
Adenocarcinoma 148 (40.8) 
Squamous 117 (32.2) 
NSCLC 63 (17.4) 
No pathology 35 (9.6) 
Location 
Right upper lobe 120 (33.1) 
Right middle lobe 28 (7.7) 
Right lower lobe 71 (19.6) 
Left upper lobe 92 (25.3) 
Left lower lobe 52 (14.3) 
T stage 
T1a 151 (41.6) 
T1b 120 (33.1) 
T2a 92 (25.3) 
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Dose fractionations (BED10) 
12 Gy x 4 (105.6 Gy) 136 33.5% 
20 Gy x 3 (180 Gy) 74 18.2% 
18 Gy x 3 (151.2 Gy) 73 18.0% 
10 Gy x 5 (100 Gy) 59 14.5% 
Other 64 15.8% 
Rx Dose* (range) 135.6 Gy (72.0-244.8) 
GTV minimum dose* (range) 152.1 Gy (77.6-292.3) 
GTV maximum dose* (range) 195.4 Gy (100.8-374.0) 
GTV mean dose* (range) 180.3 Gy (94.3-339.5) 
GTV (range) 14.2 mL (0.5-156.7) 
Local failure (range)
Days to failure 31 failures 1027.0
†
 (168-2812) 
Same lobe non-local failure (range)
 Days to failure 26 failures 778.7
†
 (26-164) 
Other ipsilateral lobe failure (range)
Days to failure 33 failures 840.0
†
 (92-2142) 
Contralateral lung failure (range)
 Days to failure 45 failures 956.0
†
 (118-3784) 
*Doses expressed in BED10.
† Mean number of days to failure
NSCLC: non-small cell lung cancer; Rx: prescription; GTV: gross tumor volume (in mL); Gy:
Gray; mL: milliliters; d: days; yr: years.
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Table 2. Univariate analysis for metastatic failure 
Variable p-value
Sex 0.36 
Age 0.40 
Current smoker 0.46 
Former smoker 0.44 
Lobe location 0.94 
T stage 0.49 
Histology 0.47 
Central vs. peripheral 0.55 
Previous NSCLC 0.84 
Rx dose 0.059 
GTV minimum dose 0.027 
GTV maximum dose 0.055 
GTV mean dose 0.044 
GTV volume 0.004 
Local failure 0.38 
Same lobe non-local failure 0.51 
Other ipsilateral lobe failure 0.37 
Contralateral lung failure 0.11 
NSCLC: non-small cell lung cancer; Rx: prescription; GTV: gross tumor volume (in mL). 
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Table 3. Multivariate Analysis for metastatic failure 
Model # Variable p-value 95% CI HR 
1 
Rx dose 0.044 0.98957–0.99997 
0.99477 
GTV volume 0.0003 1.0073-1.02518 
1.01624 
Rx: prescription; GTV: gross tumor volume (in mL). 
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Table 4. Metastases-free survival 
Low risk Medium risk High risk 
1-yr MFS 96.0% 93.8% 81.5% 
2-yr MFS 86.7% 81.3% 48.8% 
3-yr MFS 81.1% 63.8% 38.0% 
1-yr NFS 98.0% 96.2% 92.7% 
2-yr NFS 98.0% 88.7% 75.7% 
3-yr NFS 94.7% 72.8% 66.2% 
Median OS 28.2 months 19.9 months 15.5 months 
MFS: metastases-free survival (combined nodal and distant metastatic failure); NFS: nodal-
failure-free survival OS: overall survival. 
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Figure Captions 
Figure 1. Distribution of risk scores. 
Figure 2. Kaplan Meier curves for metastasis free survival according to risk score. 
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Figure S1. Combined nodal and distant failure according to centrality. 
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Figure S2. Risk of distant failure stratified by low-, medium-, and high risk in patients without a 
prior history of non-small cell lung cancer. 
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Table S1 Additional Multivariate Analysis for metastatic failure 
2 
GTV minimum dose 0.059 0.99172-1.00024 
0.99598 
GTV volume 0.002 1.0053-1.02362 
1.01446 
3 
GTV mean dose 0.042 0.99276-0.99996 
0.99630 
GTV volume 0.0005 1.00686-1.02478 
1.01582 
4 
GTV maximum dose 0.04 0.99343-0.99991 
0.99667 
GTV volume 0.0003 1.00734-1.02522 
1.01628 
Rx: prescription; GTV: gross tumor volume (in mL). 
Table S2 Prescription dose and GTV volume model 
values index.orig training test optimism index.corrected n 
Dxy  0.244937073  0.243806916 0.234935284  0.008871632 0.236065441 1000 
R2  0.036866192  0.042419252 0.033556826  0.008862426 0.028003767 1000 
Slope  1.000000000  1.000000000 0.958265124  0.041734876 0.958265124 1000 
D  0.012242654  0.014324331 0.011033412  0.003290919 0.008951736 1000 
U -0.002107209 -0.002124432 0.002471792 -0.004596224 0.002489014 1000 
Q  0.014349864  0.016448763 0.008561620  0.007887142 0.006462721 1000 
Somers’ Dxy is equal to 2* (C-index -0.5), and C-index is the concordance probability.  R2 is 
goodness of fit. D is discrimination telling the difference in quality of the best constant predictor 
and the best calibrated predictor. U is unreliability of the predictions, Q is overall summary 
showing the difference in quality between the best constant predictor and the quality of the 
predictions when no calibration was made. The c-index value is 0.618. 
